Resistance to arsenic therapy in acute promyelocytic leukemia

New England Journal of Medicine

Volumn 370, Issue 19, 2014, Pages 1864-1866

  Zhu, Hong Hu ^a   Qin, Ya Zhen ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

CANCER RESISTANCE; GENE MUTATION; HUMAN; LETTER; LEUKEMIA REMISSION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROMYELOCYTIC LEUKEMIA GENE; RETINOIC ACID RECEPTOR ALPHA GENE; SEQUENCE ANALYSIS;

ARSENICALS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MUTATION; NEOPLASM PROTEINS; OXIDES; RECEPTORS, RETINOIC ACID;

EID: 84899808285     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1316382     Document Type: Letter

References (5)

1. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369:111-21.
2. Zhu HH, Wu DP, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol 2013;31:4215-21.
3. Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010;328:240-3. [Erratum, Science 2010;328:974.]
4. Jeanne M, Lallemand-Breitenbach V, Ferhi O, et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 2010;18:88-98.
5. Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood 2011;118: 1600-9.